1. Home
  2. SNDX vs HMN Comparison

SNDX vs HMN Comparison

Compare SNDX & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$23.83

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

HOLD

Current Price

$45.13

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
HMN
Founded
2005
1945
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
SNDX
HMN
Price
$23.83
$45.13
Analyst Decision
Strong Buy
Buy
Analyst Count
13
3
Target Price
$38.69
$47.33
AVG Volume (30 Days)
1.3M
175.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
3.08%
EPS Growth
11.56
57.26
EPS
N/A
3.90
Revenue
$172,352,000.00
$1,701,400,000.00
Revenue This Year
$106.95
$7.56
Revenue Next Year
$40.94
$4.64
P/E Ratio
N/A
$11.65
Revenue Growth
627.84
6.66
52 Week Low
$8.59
$38.88
52 Week High
$25.59
$48.33

Technical Indicators

Market Signals
Indicator
SNDX
HMN
Relative Strength Index (RSI) 50.08 61.96
Support Level $22.40 $43.47
Resistance Level $25.43 $45.67
Average True Range (ATR) 1.07 0.90
MACD -0.14 0.17
Stochastic Oscillator 29.82 78.33

Price Performance

Historical Comparison
SNDX
HMN

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

Share on Social Networks: